Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics ...

This first-in-class ASO replicates the protective effects of naturally occurring CD33 loss-of-function variants, which are associated with increased resilience to neurodegenerative disease, reduced ...

The small interfering RNA (siRNA) therapy, designed to reduce triglyceride levels by suppressing production of apolipoprotein ...

As the biopharma world predominantly zeroes in on late-stage assets, Eli Lilly is prioritizing early science with the opening ...

Hire today released its 7th Annual Talent Retention Report, revealing that voluntary quits declined for the second consecutive year. However, employees are staying put ? or job hugging ? not ...

Trianz, a Transformation Services as Software company that accelerates customer business transformations with cloud, data, applications and AI capabilities, announced a major strategic validation from ...

Korro Bio saw its stock reach all-time lows on disappointing data for its lead pipeline candidate, while Intellia Therapeutics saw analyst downgrades on safety concerns despite releasing positive data ...

Arrowhead Pharmaceuticals faces key FDA decisions, legal challenges, and trial results. Read the latest analysis on the stock ...

Korro Bio delivered a double whammy of bad news, reporting lackluster data on its lead candidate and a pause to its partnership with Novo Nordisk. The biotech, which suffered a 79% stock drop in the ...

The regulator backed the medicine after phase 3 data showed dramatic reductions in HAE attacks and sustained disease control ...

PeptiSystems, a life science company developing advanced manufacturing solutions for peptide and oligonucleotide-based therapeutics, has announced a significant growth investment from Rubicon ...

Korro Bio is moving back to square one as a preclinical biotech after the failure of KRRO-110 in alpha-1 antitrypsin ...